Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phreesia, Inc.PHR · Entity 2606 | President, Network Solutions | September 01, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phreesia, Inc.
Report date September 01, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2031-09-01 | Direct | 155,000 |
Reported balance
After 2026-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 155,000 · Balance 155,000 F1: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. F2: The award was granted at a target level of 155,000 PSUs. The number of PSUs that may be earned depends on achievement of specified stock-price hurdles during the performance period beginning September 1, 2026 and ending September 1, 2031. Achievement is measured using the average closing price of the Issuer's common stock over any consecutive 60-trading-day period. Potential payouts are 0%, 50%, 100%, 150% or 200% of the target number of PSUs, subject to the award's interpolation provisions. The applicable hurdles are $17.00, $22.00, $27.00 and $32.00 per share. F3: PSUs earned with respect to an achieved hurdle vest one-third upon certification of achievement, one-third on the first anniversary of certification and one-third on the second anniversary, generally subject to continued service. Any outstanding earned PSUs vest no later than September 1, 2031. Earned and vested PSUs are settled in shares following vesting, subject to the deferred settlement provisions of the award. The actual number earned may range from zero to 200% of the target award. PSUs that are not earned by the end of the performance period are forfeited. Dividend equivalents accrue on the PSUs and are subject to the same earning and vesting conditions. Vested dividend equivalents are settled in shares when the related PSUs are settled. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.
F2: The award was granted at a target level of 155,000 PSUs. The number of PSUs that may be earned depends on achievement of specified stock-price hurdles during the performance period beginning September 1, 2026 and ending September 1, 2031. Achievement is measured using the average closing price of the Issuer's common stock over any consecutive 60-trading-day period. Potential payouts are 0%, 50%, 100%, 150% or 200% of the target number of PSUs, subject to the award's interpolation provisions. The applicable hurdles are $17.00, $22.00, $27.00 and $32.00 per share.
F3: PSUs earned with respect to an achieved hurdle vest one-third upon certification of achievement, one-third on the first anniversary of certification and one-third on the second anniversary, generally subject to continued service. Any outstanding earned PSUs vest no later than September 1, 2031. Earned and vested PSUs are settled in shares following vesting, subject to the deferred settlement provisions of the award. The actual number earned may range from zero to 200% of the target award. PSUs that are not earned by the end of the performance period are forfeited. Dividend equivalents accrue on the PSUs and are subject to the same earning and vesting conditions. Vested dividend equivalents are settled in shares when the related PSUs are settled.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2022 Filed Jan 7, 2022 21:16 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionStock Options (Right to buy) · Derivative | 24,314 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-22-000336 · primarydocument.xml · derivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,689 Underlying: Common Stock · 24,314 shares Expires 2028-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on August 7, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:16 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 5,688 | $8.03 | $45,674.64 |
DisclosureSEC source: 0001562180-22-000336 · primarydocument.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:16 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 948 | $4.71 | $4,465.08 |
DisclosureSEC source: 0001562180-22-000336 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:16 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 24,314 | $4.71 | $114,518.94 |
DisclosureSEC source: 0001562180-22-000336 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 21:50 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionStock Option · Derivative | 1,499 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-21-006937 · primarydocument.xml · derivative · entry 6 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,423 Underlying: Common Stock · 1,499 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 21:50 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 1,499 | $75.12 | $112,606.98 |
DisclosureSEC source: 0001562180-21-006937 · primarydocument.xml · nonDerivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.32 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 21:50 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 1,499 | $4.71 | $7,060.29 |
DisclosureSEC source: 0001562180-21-006937 · primarydocument.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:50 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionStock Option · Derivative | 3,478 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-21-006937 · primarydocument.xml · derivative · entry 5 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,922 Underlying: Common Stock · 3,478 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:50 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 3,478 | $75.15 | $261,382.48 |
DisclosureSEC source: 0001562180-21-006937 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:50 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 3,478 | $4.71 | $16,381.38 |
DisclosureSEC source: 0001562180-21-006937 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:37 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionStock Option · Derivative | 5,451 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-21-006772 · primarydocument.xml · derivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,400 Underlying: Common Stock · 5,451 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:37 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 3,077 | $71.23 | $219,187.02 |
DisclosureSEC source: 0001562180-21-006772 · primarydocument.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.85 to $71.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:37 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 2,374 | $70.42 | $167,174.71 |
DisclosureSEC source: 0001562180-21-006772 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,465 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.85 to $70.79 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:37 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 5,451 | $4.71 | $25,674.21 |
DisclosureSEC source: 0001562180-21-006772 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 15, 2021 Filed Oct 15, 2021 22:33 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionStock Option · Derivative | 5,452 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-21-006476 · primarydocument.xml · derivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,851 Underlying: Common Stock · 5,452 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| October 15, 2021 Filed Oct 15, 2021 22:33 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 5,452 | $65.36 | $356,334.00 |
DisclosureSEC source: 0001562180-21-006476 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.67 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 15, 2021 Filed Oct 15, 2021 22:33 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 5,452 | $4.71 | $25,678.92 |
DisclosureSEC source: 0001562180-21-006476 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:01 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionStock Option · Derivative | 4,978 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-21-005742 · primarydocument.xml · derivative · entry 8 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,303 Underlying: Common Stock · 4,978 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:01 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 333 | $71.39 | $23,773.57 |
DisclosureSEC source: 0001562180-21-005742 · primarydocument.xml · nonDerivative · entry 6 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.29 to $71.41 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:01 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 3,204 | $70.67 | $226,424.12 |
DisclosureSEC source: 0001562180-21-005742 · primarydocument.xml · nonDerivative · entry 5 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,721 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.25 to $71.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:01 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 1,441 | $69.63 | $100,337.26 |
DisclosureSEC source: 0001562180-21-005742 · primarydocument.xml · nonDerivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,925 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.21 to $70.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:01 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 4,978 | $4.71 | $23,446.38 |
DisclosureSEC source: 0001562180-21-005742 · primarydocument.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:01 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionStock Option · Derivative | 474 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-21-005742 · primarydocument.xml · derivative · entry 7 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,281 Underlying: Common Stock · 474 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:01 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 474 | $71.84 | $34,052.16 |
DisclosureSEC source: 0001562180-21-005742 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:01 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 474 | $4.71 | $2,232.54 |
DisclosureSEC source: 0001562180-21-005742 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:41 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionStock Option · Derivative | 21,455 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001562180-21-005666 · primarydocument.xml · derivative · entry 6 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,455 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:41 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 200 | $73.05 | $14,610.00 |
DisclosureSEC source: 0001562180-21-005666 · primarydocument.xml · nonDerivative · entry 5 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:41 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 11,987 | $72.36 | $867,343.36 |
DisclosureSEC source: 0001562180-21-005666 · primarydocument.xml · nonDerivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,588 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.02 to $73.01 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:41 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 5,336 | $71.70 | $382,579.46 |
DisclosureSEC source: 0001562180-21-005666 · primarydocument.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,575 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.01 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:41 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 3,932 | $70.46 | $277,066.41 |
DisclosureSEC source: 0001562180-21-005666 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,911 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:41 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 21,455 | $2.55 | $54,710.25 |
DisclosureSEC source: 0001562180-21-005666 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 26, 2021 Filed Aug 28, 2021 00:08 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001562180-21-005622 · primarydocument.xml · derivative · entry 6 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,455 Underlying: Common Stock · 800 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| August 26, 2021 Filed Aug 28, 2021 00:08 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 800 | $70.07 | $56,054.00 |
DisclosureSEC source: 0001562180-21-005622 · primarydocument.xml · nonDerivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.18 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 26, 2021 Filed Aug 28, 2021 00:08 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 800 | $2.55 | $2,040.00 |
DisclosureSEC source: 0001562180-21-005622 · primarydocument.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 25, 2021 Filed Aug 28, 2021 00:08 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001562180-21-005622 · primarydocument.xml · derivative · entry 5 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,255 Underlying: Common Stock · 500 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| August 25, 2021 Filed Aug 28, 2021 00:08 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 500 | $70.04 | $35,019.00 |
DisclosureSEC source: 0001562180-21-005622 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 25, 2021 Filed Aug 28, 2021 00:08 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 500 | $2.55 | $1,275.00 |
DisclosureSEC source: 0001562180-21-005622 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 04, 2021 Filed May 5, 2021 22:54 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionStock Options (Right to buy) · Derivative | 22,755 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001562180-21-003274 · primarydocument.xml · derivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,755 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| May 04, 2021 Filed May 5, 2021 22:54 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionStock Option · Derivative | 22,755 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001562180-21-003274 · primarydocument.xml · derivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,755 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| May 04, 2021 Filed May 5, 2021 22:54 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 22,755 | $2.03 | $46,192.65 |
DisclosureSEC source: 0001562180-21-003274 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 04, 2021 Filed May 5, 2021 22:54 UTC | Phreesia, Inc. PHR · Entity 2606 | Exercise / conversionCommon Stock | 22,755 | $0.84 | $19,114.20 |
DisclosureSEC source: 0001562180-21-003274 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 20:28 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 300 | $61.31 | $18,393.00 |
DisclosureSEC source: 0000899243-21-012177 · doc4.xml · nonDerivative · entry 5 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,580 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.07 to $61.53 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU respesents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 20:28 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 500 | $60.62 | $30,312.00 |
DisclosureSEC source: 0000899243-21-012177 · doc4.xml · nonDerivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,880 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.07 to $61.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU respesents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 20:28 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 778 | $58.51 | $45,518.99 |
DisclosureSEC source: 0000899243-21-012177 · doc4.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,380 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.23 to $59.17 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU respesents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:28 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 6,706 | $61.69 | $413,721.31 |
DisclosureSEC source: 0000899243-21-012177 · doc4.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,158 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.50 to $62.23 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU respesents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:28 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 41,776 | $61.06 | $2,550,788.25 |
DisclosureSEC source: 0000899243-21-012177 · doc4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,864 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.50 to $61.47 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU respesents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 22:32 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 6,282 | $66.14 | $415,514.72 |
DisclosureSEC source: 0000899243-21-002979 · doc4.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,640 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.57 to $66.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent RSUs. Each RSU respesents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 22:32 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 544 | $64.86 | $35,283.08 |
DisclosureSEC source: 0000899243-21-002979 · doc4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,922 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.36 to $65.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent RSUs. Each RSU respesents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 01:31 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 5,136 | $64.28 | $330,119.48 |
DisclosureSEC source: 0000899243-21-002578 · doc4.xml · nonDerivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,466 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.2013 to $64.2850 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent RSUs. Each RSU respesents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 17, 2021 Filed Jan 21, 2021 01:31 UTC | Phreesia, Inc. PHR · Entity 2606 | Tax withholdingCommon Stock | 277 | $62.96 | $17,439.92 |
DisclosureSEC source: 0000899243-21-002578 · doc4.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,602 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU respesents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.